PO.MCB03.01 · 分子与细胞生物学

通过靶向K-RAS通路的一个主要肿瘤脆弱性——Seven in absentia homolog (SIAH)——根除转移性癌症

Eradicating metastatic cancers by targeting a major tumor vulnerability of the K-RAS pathway: Seven in absentia homolog (SIAH)

海报缩略图:通过靶向K-RAS通路的一个主要肿瘤脆弱性——Seven in absentia homolog (SIAH)——根除转移性癌症
编号 5982 展板 7 时间 4/21 02:00–05:00 区域 Section 23 主讲 Jonathan Baker, BA
分会场 RAS/MAPK Signaling, KRAS Targeting, and Adaptive Resistance
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Jonathan M. Baker1, Emanuel Frank Petricoin2, Julia Wulfkhule2, Andrew Howell3, Ashleigh Hannah3, Amy H. Tang4

1Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School at Old Dominion University, Norfolk, VA,2George Mason University, Manassas, VA,3Eastern Virginia Medical School, Norfolk, VA,4Old Dominion University, Norfolk, VA

摘要 Abstract

中文摘要
背景:K-RAS通路的持续激活具有多能性:其下游信号网络促进肿瘤发生、耐药、复发和转移。尽管新近开发了多种最先进的疗法,但目前尚无一种能够实现持久的抗肿瘤疗效。Seven in absentia homologues (SIAHs)是一个保守的RING结构域E3泛素连接酶家族,作为K-RAS通路中最下游的信号守门者发挥作用。我们的临床前研究表明,抑制SIAH可在体外和体内导致多种IV期人类癌细胞系出现肿瘤根除表型。 目的:我们提出SIAH是抑制K-RAS通路激活的一个主要肿瘤脆弱性和可成药的靶点。在本研究中,我们旨在阐明我们强效SIAH抑制剂SIAH 2 PD抗肿瘤疗效背后的分子机制,作为一种实现肿瘤根除的新型靶向疗法。 方法:采用反相蛋白质芯片(RPPAs)和主成分分析(PCA)对五个IV期细胞系中294种信号蛋白和磷酸化蛋白在SIAH阻断后具有统计学意义的倍数变化进行定量。RPPAs在MiaPaCa、MDA-MB-231、MDA-MB-468、HeLa和A459细胞系上一式三份进行,其中SIAH 2 PD的表达由多西环素(DOX)诱导型Tet-ON/OFF系统控制。使用了四种实验条件:不加DOX的Tet-ON载体对照细胞(A组)和加DOX诱导的细胞(B组);不加DOX的Tet-ON-SIAH 2 PD实验细胞(C组)和加DOX诱导的细胞(D组)。在以GAPDH作为内参进行标准化后,通过两两比较计算各组的比值。为验证感兴趣的候选靶点,对C组和D组细胞在DOX诱导后第3、5和7天进行免疫荧光(IF)、流式细胞术(FC)和Western blot(WB)检测。分别使用贴壁细胞和单细胞悬液进行基于细胞的检测,以生物学三次重复进行,并以alpha-Tubulin标准化。对靶蛋白表达进行定量和验证,并使用GraphPad Prism软件通过单因素ANOVA和T检验进行统计学分析。 结果:NFκB、Caspase-3、Caspase-7、Cofilin和PARP在SIAH阻断后表达的改变通过RPPA、WB、FC和IF得到独立验证,表明SIAH功能丧失所诱导的细胞应激加剧、凋亡以及DNA损伤修复通路功能障碍在机制上协同发挥作用,杀死癌细胞并阻止肿瘤生长。 结论:RPPA癌症通路图谱为SIAH阻断后癌症网络重连提供了宝贵的分子见解,揭示了一个主要的肿瘤脆弱性。本研究支持设计基于抗SIAH的抗EGFR/K-RAS靶向疗法,以控制和根除无法治愈的人类癌症。
查看英文原文 English abstract
Background: Persistent activation of the K-RAS pathway is multipotent: its downstream signaling networks promote tumorigenesis, drug resistance, relapse, and metastasis. Despite newly developed state-of-the-art therapies, none have yet to achieve durable antitumor efficacy. Seven in absentia homologues (SIAHs) are a conserved family of RING-domain E3 ubiquitin ligases that function as the most downstream signaling gatekeepers in the K-RAS pathway. Our preclinical studies demonstrated that SIAH inhibition leads to a tumor eradication phenotype of multiple stage IV human cancer cell lines both in vitro and in vivo. Aims: We propose SIAH is a major tumor vulnerability and actionable drug target for inhibiting K-RAS pathway activation. In this study, we aim to elucidate the molecular mechanisms underpinning the antitumor efficacy of our potent SIAH inhibitor, SIAH 2 PD , as a new targeted therapy to achieve tumor eradication. Methods: Reverse phase protein arrays (RPPAs) and principal component analysis (PCA) were used to quantify statistically significant fold-changes of 294 signaling proteins and phospho-proteins in response to SIAH blockade in five stage IV cell lines. RPPAs were performed in triplicate on MiaPaCa, MDA-MB-231, MDA-MB-468, HeLa, and A459 cell lines in which SIAH 2 PD expression was controlled by a doxycycline (DOX)-inducible Tet-ON/OFF system. Four experimental conditions were used: Tet-ON vector control cells without DOX ( group A ) and with DOX induction ( group B ); Tet-ON-SIAH 2 PD experimental cells without DOX ( group C ) and with DOX induction ( group D ). The ratios of each group were calculated in a pairwise comparison after normalization to GAPDH as an internal control. To validate putative targets of interest, immunofluorescence (IF), flow cytometry (FC), and Western blots (WB) were performed on cells for group C and D at 3-, 5-, and 7-days post-DOX-induction. Adherent and single cell suspensions were used respectively for cell-based assays in biological triplicates and normalized to alpha-Tubulin. Target protein expression was quantified and validated, and statistical analyses were performed by one-way ANOVA and T-tests using GraphPad Prism software. Results: The altered expression of NFκB, Caspase-3, Caspase-7, Cofilin, and PARP in response to SIAH blockade were independently validated by RPPA, WB, FC, and IF, demonstrating the roles of heightened cellular stress, apoptosis, and dysfunctional DNA damage and repair pathways induced by SIAH loss of function as mechanistic, synergistic to kill cancer cells and prevent tumor growth. Conclusions: RPPA cancer pathway mapping provides invaluable molecular insights into cancer network rewiring in response to SIAH blockade, revealing a major tumor vulnerability. This study supports the design of anti-SIAH-based, anti-EGFR/K-RAS targeted therapies to control and eradicate incurable human cancers.
利益披露 Disclosure
J. M. Baker, None.

← 返回 AACR 2026 检索